Melanoma News and Research

Latest Melanoma News and Research

New extra potent sunscreens in the pipeline

Sunscreens are touted to protect your skin from the harmful ultraviolet rays of the sun. However scientists are now studying whether a good sunscreen protects your skin even after your skin is no longer exposed to the sun? This study is undertaken because of the alarming rise in malignant melanoma, a form of skin cancer that is linked to the sun’s UV rays. Malignant melanoma is the most common cancer in Australia and Queensland tops all other places in the world when it comes to incidence of this skin cancer.

7 Apr 2010

FDA grants "Fast Track" designation for Genta’s advanced gastric cancer drug tesetaxel

Genta Incorporated today announced that the U.S. Food and Drug Administration (FDA) has granted the Company's request for "Fast Track" designation of tesetaxel for treatment of patients with advanced gastric cancer. Tesetaxel -- a late Phase 2 oncology product -- is the leading oral taxane currently in clinical development.

7 Apr 2010

Johns Hopkins Kimmel Cancer Center reviews top cancer stories

Surgeon Jeremy Richmon, M.D., at Johns Hopkins is using robotic assistance to cut away tumors of the tongue and tonsils. Conventional surgery leaves disfiguring neck and jaw scars, but the robotic procedure leaves no scar except for inside the mouth, and he says, patients retain good function of speech and swallowing.

5 Apr 2010

Cancer Prevention Coalition's statement on new nominated NCI Director

Last Wednesday, the White House nominated Nobel Laureate Harold Varmus as Director of the National Cancer Institute.

3 Apr 2010

People in 60s and 70s more likely to be diagnosed with skin cancer

People in their 60s and 70s are now over five times more likely to be diagnosed with malignant melanoma - the deadliest type of skin cancer - than their parents would have been 30 years ago, reveal new Cancer Research UK statistics1 to launch the 2010 SunSmart campaign today (Thursday).

1 Apr 2010

Genta commences Phase 2b trial of tesetaxel in patients with advanced gastric cancer

Genta Incorporated today announced that the Company has initiated a confirmatory Phase 2b trial of tesetaxel in patients with advanced gastric cancer. Tesetaxel is the Company's newest clinical-stage small molecule. As a late Phase 2 oncology product, tesetaxel is the leading oral taxane currently in clinical development.

31 Mar 2010

Enrollment complete in Gemin X Pharmaceuticals' Phase 2 clinical trial of obatoclax for SCLC

Gemin X Pharmaceuticals, a clinical stage biopharmaceutical company developing novel, targeted cancer therapeutics, today announced the completion of patient enrollment in a Phase 2 clinical trial of the Company's lead product candidate obatoclax (GX15-070) for the treatment of extensive-stage small cell lung cancer (SCLC). The trial is designed to evaluate the efficacy and safety of obatoclax, a novel pan Bcl-2 inhibitor, in combination with standard chemotherapy for the first-line treatment of patients with SCLC.

29 Mar 2010

Upgrading to policy with no limits benefits insurance agent

It can be instructive to consider not just what long term care insurance professionals recommend, but what they do -- for their own personal protection. A good example is the case of Kim Galatolo, an agent with LTC Financial Partners LLC one of the nation's most experienced long term care insurance agencies. In California, where Galatolo lives and works, the firm is known as LTC Partners & Insurance Services, LLC.

29 Mar 2010

Genta reports net loss of $11.7M for fourth-quarter 2009

Genta Incorporated today reported results for the quarter and year ended December 31, 2009. The Company also provided an overview of recent corporate highlights and anticipated milestones.

29 Mar 2010

Strong lobbying efforts by tanning bed industry a barrier to passage of legislation

Researchers from Boston University School of Medicine (BUSM) have found that when attempting to pass tanning bed legislation, successful advocates collaborate with local and national organizations and lobbyists and have direct contact with the sponsoring legislator to aid in the passage of the bill. These findings, which appear on-line in the Journal of the American Academy of Dermatology, also identify strong lobbying efforts by the tanning bed industry as the biggest barrier to passing tanning bed legislation.

27 Mar 2010

Indoor tanning devices: AADA testifies before FDA panel on needed classification changes and calls for ban

American Academy of Dermatology Association (AADA) President and dermatologist William D. James, MD, FAAD, along with other dermatologists and leading researchers today testified before a Food and Drug Administration (FDA) panel considering changes to the current classification of indoor tanning devices. Currently, the FDA classifies indoor tanning devices as Class 1, the category for items that have minimal potential to cause harm to individuals. Items in Class 1 include adhesive bandages and tongue depressors.

27 Mar 2010

Two separate articles describing preclinical data of ACE-041 published

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the vasculature, announced the publication of two separate peer-reviewed articles describing preclinical data demonstrating that treatment with ACE-041, an inhibitor of signaling through the activin receptor-like kinase 1 receptor, slows tumor growth and progression by inhibiting angiogenesis.

26 Mar 2010

Single dose of Pain Therapeutics' PTI-188 decreased melanoma tumors: Study

Pain Therapeutics, Inc. today announced encouraging clinical data with PTI-188, an early-stage drug for metastatic melanoma. Metastatic melanoma is a lethal form of skin cancer in which patients typically have a median survival time of 9 months.

24 Mar 2010

Nanotechnology weapons for cancer

US Researchers have come up with new nanoparticle robots that are essentially a tiny army that can travel in the blood till they reach the cancers and then tweak some important cancer causing genes that can cure the cancer.

22 Mar 2010

ASCO Scientific Program 2010: Provectus Pharmaceuticals' Phase 2 data on PV-10 accepted for presentation

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that data from its Phase 2 study of PV-10 for metastatic melanoma has been accepted for presentation at the 2010 American Society of Clinical Oncology (ASCO) Scientific Program to be held on June 4 – 8, 2010 in Chicago, Illinois.

19 Mar 2010

Abraxis BioScience's Phase 3 trial comparing ABRAXANE with Taxol injection meets primary endpoint

Abraxis BioScience, Inc. today announced that its randomized registrational Phase 3 clinical trial comparing ABRAXANE® (protein-bound paclitaxel) with Taxol® (paclitaxel) injection, both in combination with carboplatin, met the study’s primary endpoint by demonstrating that ABRAXANE showed a significant improvement in overall response rate as compared to Taxol, in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC), as assessed by independent radiologist review.

17 Mar 2010

Sunbeds Bill to prevent under-18s from using tanning salons receives high-profile support

A Bill to prevent under-18s from using tanning salons has cleared its stages in the House of Commons, and will now go for consideration in the House of Lords.

17 Mar 2010

Research suggests anti-cancer drugs can help treat infectious diseases

Drugs increasingly used to treat cancer could have a major impact on a wide range of infectious diseases, according to new research.

16 Mar 2010

Study offers new possibilities for breast and other cancer therapies

Conventional biological wisdom holds that living cells interact with their environment through an elaborate network of chemical signals. As a result many therapies for the treatment of cancer and other diseases in which cell behavior goes awry focus on drugs that block or disrupt harmful chemical signals.

16 Mar 2010

Metastatic melanoma: Involvement of immune system in response to PV-10 therapy

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that Dr. Sanjiv Agarwala, in his presentation at the Seventh International Symposium on Melanoma and Other Cutaneous Malignancies on March 12, 2010, commented on the involvement of the immune system in response to PV-10 therapy and its role in the “bystander effect” in treating metastatic melanoma. Dr. Agarwala’s presentation, entitled “Chemoablation in Melanoma: An Update,” was given in the session entitled “Unique Approaches to Melanoma Therapy.”

15 Mar 2010

Melanoma News and Research

Latest Melanoma News and Research

New extra potent sunscreens in the pipeline

FDA grants "Fast Track" designation for Genta’s advanced gastric cancer drug tesetaxel

Johns Hopkins Kimmel Cancer Center reviews top cancer stories

Cancer Prevention Coalition's statement on new nominated NCI Director

People in 60s and 70s more likely to be diagnosed with skin cancer

Genta commences Phase 2b trial of tesetaxel in patients with advanced gastric cancer

Enrollment complete in Gemin X Pharmaceuticals' Phase 2 clinical trial of obatoclax for SCLC

Upgrading to policy with no limits benefits insurance agent

Genta reports net loss of $11.7M for fourth-quarter 2009

Strong lobbying efforts by tanning bed industry a barrier to passage of legislation

Indoor tanning devices: AADA testifies before FDA panel on needed classification changes and calls for ban

Two separate articles describing preclinical data of ACE-041 published

Single dose of Pain Therapeutics' PTI-188 decreased melanoma tumors: Study

Nanotechnology weapons for cancer

ASCO Scientific Program 2010: Provectus Pharmaceuticals' Phase 2 data on PV-10 accepted for presentation

Abraxis BioScience's Phase 3 trial comparing ABRAXANE with Taxol injection meets primary endpoint

Sunbeds Bill to prevent under-18s from using tanning salons receives high-profile support

Research suggests anti-cancer drugs can help treat infectious diseases

Study offers new possibilities for breast and other cancer therapies

Metastatic melanoma: Involvement of immune system in response to PV-10 therapy

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Melanoma News and Research

Latest Melanoma News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in